• SPX
  • $5,968.55
  • 0.33 %
  • $19.84
  • DJI
  • $44,167.34
  • 0.68 %
  • $296.98
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,259.86
  • 1.36 %
  • $110.59
  • IXIC
  • $19,000.42
  • 0.15 %
  • $28.00
Foghorn Therapeutics Inc. (FHTX) Stock Price, News & Analysis

Foghorn Therapeutics Inc. (FHTX) Stock Price, News & Analysis

Currency in USD Disclaimer

$7.92

$0.2

(2.59%)

Day's range
$7.55
Day's range
$7.92
50-day range
$6.94
Day's range
$10.25
  • Country: US
  • ISIN: US3441741077
52 wk range
$2.7
Day's range
$10.25
  • CEO: Mr. Adrian H. B. Gottschalk
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -1.86
  • Piotroski Score 0.00
  • Grade Buy
  • Symbol (FHTX)
  • Company Foghorn Therapeutics Inc.
  • Price $7.92
  • Changes Percentage (2.59%)
  • Change $0.2
  • Day Low $7.55
  • Day High $7.92
  • Year High $10.25

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/06/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $20.00
  • High Stock Price Target $20.00
  • Low Stock Price Target $9.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.20
  • Trailing P/E Ratio -2.73
  • Forward P/E Ratio -2.73
  • P/E Growth -2.73
  • Net Income $-98,426,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Foghorn Therapeutics Inc. Frequently Asked Questions

  • What were the earnings of FHTX in the last quarter?

    In the last quarter Foghorn Therapeutics Inc. earnings were on Monday, November, 4th. The Foghorn Therapeutics Inc. maker reported -$0.31 EPS for the quarter, beating analysts' consensus estimates of -$0.42 by $0.11.

  • What is the Foghorn Therapeutics Inc. stock price today?

    Today's price of Foghorn Therapeutics Inc. is $7.92 — it has increased by +2.59% in the past 24 hours. Watch Foghorn Therapeutics Inc. stock price performance more closely on the chart.

  • Does Foghorn Therapeutics Inc. release reports?

    Yes, you can track Foghorn Therapeutics Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Foghorn Therapeutics Inc. stock forecast?

    Watch the Foghorn Therapeutics Inc. chart and read a more detailed Foghorn Therapeutics Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Foghorn Therapeutics Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Foghorn Therapeutics Inc. stock ticker.

  • How to buy Foghorn Therapeutics Inc. stocks?

    Like other stocks, FHTX shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Foghorn Therapeutics Inc.'s EBITDA?

    Foghorn Therapeutics Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Foghorn Therapeutics Inc.’s financial statements.

  • What is the Foghorn Therapeutics Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -2.8817449861, which equates to approximately -288.17%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Foghorn Therapeutics Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Foghorn Therapeutics Inc.'s financials relevant news, and technical analysis. Foghorn Therapeutics Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Foghorn Therapeutics Inc. stock currently indicates a “sell” signal. For more insights, review Foghorn Therapeutics Inc.’s technical analysis.

  • A revenue figure for Foghorn Therapeutics Inc. for its last quarter?

    Foghorn Therapeutics Inc. published it's last quarterly revenues at $7.81 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.